The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial fibrillation (AF). Direct comparisons between NOACs in trials are lacking, leaving an important clinical decision-making gap. We aimed to perform a systematic review and meta-analysis to summarize the evidence of observational studies for direct comparative effectiveness and safety amongst NOACs in patients with AF. Conference proceedings and electronic databases including MEDLINE, CINAHL, EMBASE and PUBMED were systematically searched. We included observational studies directly comparing individual NOACs in patients with nonvalvular AF who were aged C 18 years for stroke prevention. Primary outcome included effectiveness outcome (stroke or systemic embolism) and safety outcome (major bleeding). Data were extracted in duplicated by two reviewers independently. A random-effects meta-analysis was conducted to synthesize the data from included observational studies. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) to rate the overall quality of evidence for each outcome. Fifteen studies were included for qualitative synthesis, twelve studies for meta-analyses. It was found that rivaroxaban and dabigatran were similar with regard to risk of stroke or systemic embolism (Hazard ratio [HR] = 1.00, 95% CI 0.91-1.10; evidence quality: low), but rivaroxaban was associated with higher risk of major bleeding (HR = 1.39, 95% CI 1.28-1.50; evidence quality: moderate). Compared with apixaban, a significantly higher risk of major bleeding was observed with rivaroxaban (HR = 1.71, 95% CI 1.51-1.94; evidence quality: low). Apixaban was associated with lower risk of major bleeding, in comparison with dabigatran (HR = 0.80, 95% CI 0.68-0.95; evidence quality: low). No differences in risk of stroke or systemic embolism was observed between rivaroxaban versus apixaban, and apixaban versus dabigatran. In this study, apixaban was found to have the most favorable safety profile amongst the three NOACs. No significant difference was observed in risk of stroke or systemic embolism between the NOACs. Such findings may provide some decision-making support for physicians regarding their choices amongst NOACs in patients with AF.
Introduction
Atrial fibrillation (AF) is a highly prevalent, age-related cardiac arrhythmia and independently increases the risk of stroke by five fold [1, 2] . The use of antithrombotic prophylaxis remains the mainstay to prevent stroke in patients with nonvalvular AF [3, 4] . The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly prescribed in clinical practice, due to their advantages over warfarin such as the decreased need for monitoring, fewer food and drug interactions, and more predictable pharmacodynamic effect [5] [6] [7] .
The efficacy and safety of NOACs compared with warfarin have been presented in respective multicenter Phase III randomized controlled trials (RCTs) [8] [9] [10] [11] . However, no head-to-head comparison between NOACs is available from RCTs; therefore there is a lack of direct clinical outcome evidence to inform physicians and patients on the choice amongst NOACs. Some studies employed the RCT data to conduct indirect comparison analyses for relative effect estimates between NOACs by using the common comparator arm (warfarin) in all the trials [12] [13] [14] [15] [16] [17] [18] . Nevertheless, the utility and credibility of their results are limited given the difference in populations, outcomes, study methodology and designs, and time in therapeutic range in warfarin groups between the respective RCTs [19, 20] . Besides, whether and how NOACs in real-world circumstances would show different effectiveness-safety profiles from those in the ideal RCT settings, and whether similar comparative effectiveness-safety profiles would be observed amongst NOACs, remains to be further explored. Observational studies provide a platform for direct comparative evaluation amongst NOACs in heterogeneous populations in real-world clinical practice, which could supply some evidence to physicians to aid in decision-making regarding their choices amongst NOACs.
In this study, we aimed to conduct a systematic review and meta-analysis to summarize the evidence of direct comparison from observational studies for the comparative effectiveness and safety between NOACs in patients with nonvalvular AF.
Methods
We conducted this study based on guidance from the Cochrane Handbook of Systematic Reviews and reported results according to PRISMA (the Preferred Reporting Items for Systematic Reviews and Meta-analyses) recommendations [21, 22] . The study protocol was registered in PROSPERO (Prospective Register of Ongoing Systematic Reviews; identifier: CRD42016052908).
Search strategy
We searched the following electronic databases to identify eligible observational studies: MEDLINE, CINAHL and EMBASE from Jan 1st, 2009 to November 30th, 2016, because the first NOAC (dabigatran) in AF was reported for licensing in 2009 [10] . We also updated the PUBMED search from November 2016 up to August 3rd, 2017. We used descriptors including synonyms for observational studies, NOACs, stroke or bleeding, and atrial fibrillation in the search (detailed terms for search were presented in Supplemental Table 1 ). Reference lists of included studies and other review or editorial articles were also searched for relevant reports. No language restriction was used. 
Study eligibility criteria
Case-control and cohort studies directly comparing individual NOACs in patients with nonvalvular AF who were aged C 18 years for stroke prevention were eligible for inclusion. We focused on factor Xa inhibitors (rivaroxaban, edoxaban, and apixaban) and the direct thrombin inhibitor (dabigatran). Therefore the comparisons amongst NOACs included dabigatran versus rivaroxaban, dabigatran versus apixaban, dabigatran versus edoxaban, rivaroxaban versus apixaban, rivaroxaban versus edoxaban, and apixaban versus edoxaban.
If data from the same participants were published in multiple reports or at different time points, we chose the study with the largest sample size and longest follow-up. We excluded studies if their objectives were not comparative effectiveness or safety profiles of NOACs, or if they could not provide data on comparative effectiveness or safety amongst NOACs in patients with AF. Moreover, some studies may compare one NOAC (e.g., dabigatran) with a combination of the other NOACs (e.g., rivaroxaban and apixaban). These studies were not included if no data on direct comparison (e.g., dabigatran vs. rivaroxaban, or dabigatran vs. apixaban) could be isolated or extracted. Furthermore, we excluded studies comparing NOACs in patients for cardioversion or ablation of AF, because of their short-term treatment duration and follow-up.
Outcomes
In this study, the primary outcomes included the effectiveness outcome (a composite of stroke or systemic embolism) and the safety outcome (a composite of major bleeding). Given that the included studies may define primary outcomes differently, we adopted the definitions from the included individual studies and presented their definitions in Table 1 . Our secondary outcomes were myocardial infarction (MI) and all-cause mortality.
Data extraction and individual study quality assessment
Two reviewers (G.L. and Y.C.) independently screened and chose eligible studies for inclusion. We used the Kappa statistic to quantify the agreement between the two reviewers [23] . Disagreement was addressed by discussion between the two reviewers, with a third arbiter available if no consensus could be reached. The two reviewers extracted data independently including information on study design, patient characteristics, anticoagulant information, outcome assessment, follow-up period, and comparative treatment effect estimates.
The Cochrane Collaboration ROBINS-I (Risk of Bias In Non-randomized Studies-of Interventions) evaluation tool was used to assess the individual observational study quality [24] . Each study was rated as either low, moderate, serious, or critical risk of bias, according to the domains of confounding, participant selection, intervention classification, departure from intended intervention, missing data, outcome measures, and selective reporting.
Statistical analyses
We performed a random-effects meta-analysis to synthesize the data by pooling the results of the cohort and casecontrol studies, respectively. We used the adjusted hazard ratios (HRs) for cohort studies and odds ratios (ORs) for case-control studies for meta-analyses. Treatment effect estimates were reported with pooled HRs and ORs for cohort studies and case-control studies respectively, each with 95% confidence intervals (CIs).
Data on the composite outcomes may not be extracted in some studies, because they may only report individual components of the composite outcomes (e.g., they presented results for stroke and systemic embolism respectively). For these studies, we only pooled data on stroke for effectiveness outcome, and intracranial hemorrhage (ICH) for safety outcome respectively, to avoid duplicate counting of the same patients with multiple events in the metaanalyses [25] . Likewise, if multiple doses of a NOAC were studied and not combined, we included data only on the highest dose for meta-analysis.
Statistical heterogeneity for included studies was estimated using the I 2 statistic, in which a p value of less than 0.1 or an I 2 of over 50% indicated significant heterogeneity [21] . Assessment of publication bias and quality of a body of evidence across included studies
We used the Begg's rank correlation and Egger's regression tests for primary outcomes to evaluate potential publication bias statistically [21] . Funnel plots were also constructed for visual inspection of asymmetry. The quality of a body of evidence for this study was rated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool [26] . The quality of evidence across included studies could be categorized as very low, low, moderate, or high, based on the judgement about the study design, directness of evidence, precision of results, inconsistency of results or unexplained heterogeneity, and publication bias [26] .
Results
There were 1449 records included for screening. After title and abstract screening and duplicate removal, we assessed a total of 92 full-text articles for eligibility with an interrater Kappa statistic of 0.80 (95% CI 0.63-0.97) between the assessors. Fifteen studies (nine full texts [20, [27] [28] [29] [30] [31] [32] [33] [34] and six abstracts [35] [36] [37] [38] [39] [40] ) were eligible to be included for qualitative synthesis, among which there were twelve studies (seven full texts [20, 28, [30] [31] [32] [33] [34] and five abstracts [35, [37] [38] [39] [40] ) included for quantitative synthesis (Supplemental Figure 1 ). Table 1 shows characteristics of the fifteen included studies. Most studies (n = 14) were retrospective cohort designs using data from electronic health databases, while only one study was prospective cohort research [34] . Thirteen studies focused on NOAC-naive users. All the primary outcome measures were identified from ICD-9- Direct comparative effectiveness and safety between non-vitamin K antagonist oral… 177 
Cox survival regression
Direct comparative effectiveness and safety between non-vitamin K antagonist oral… 181 . No studies provided data on edoxaban, reflecting its very recent approval. For rivaroxaban versus dabigatran, the included studies were conducted in USA (n = 10), China (n = 3), Denmark (n = 1) and Sweden (n = 1). Patients had a median age of approximately 72 years, with a median CHADS 2 score of 2 and a median HAS-BLED score of 2. The follow-up period varied from 110 days to 400 days. Studies with data on rivaroxaban versus apixaban or apixaban versus dabigatran were performed in USA (n = 8) and Sweden (n = 1). Patients' median age was 73 years, median CHADS 2 score 2 and median HAS-BLED score 2. Only one study provided data on follow-up period of approximately 160 days [31] . Among all the included studies, eight used multivariable survival regression, six propensity score method, and one multivariable logistic regression to quantify comparative evaluation amongst NOACs, respectively (Table 1 ). Study quality was evaluated for the nine full texts. Seven studies were rated as low-risk-of-bias for effectiveness and safety outcomes [20, 28, 29, 31, 32] . There was one study [30] rated as moderate-risk-of-bias for stoke or systemic embolism because it did not provide information on missing data and it measured transient ischemic attack as a component of effectiveness outcome. One study [27] was graded as moderate-risk-of-bias for safety outcomes because of the potential selective reporting and no information on missing data. Figure 1 and Table 2 display results of comparative effectiveness and safety between rivaroxaban and dabigatran. Seven studies that provided data on HRs were synthesized, while the other study [29] that reported adjusted ORs was not included for meta-analyses. No significant difference in risk of stroke or systemic embolism was found between rivaroxaban and dabigatran (HR = 1.00, 95% CI 0.91-1.10, p = 0.97; Fig. 1a ). There was marginally significant heterogeneity observed for risk of stroke or systemic embolism (I 2 = 44%, p value = 0.1). Compared with dabigatran, rivaroxaban was significantly associated with increased risk of major bleeding (HR = 1.39, 95% CI 1.28-1.50, p \ 0.001; Fig. 1b) . Regarding secondary outcomes, no significant difference was found in risk of MI between rivaroxaban and dabigatran (HR = 0.87, 95% CI 0.72-1.05, p = 0.15; Supplemental Figure 2) , while a higher risk of all-cause death was found with rivaroxaban (HR = 1.28, 95% CI 1.14-1.43, p \ 0.001; Supplemental Figure 3 ). No statistically significant heterogeneity was found for risks of major bleeding, MI and death, with all the I 2 of \ 50% and p values of [ 0.1. Likewise, as shown in Table 2 , rivaroxaban was nonsignificantly associated with risk of stroke, but significantly associated with increased risk of major GI bleeding, compared with dabigatran. However, no significant association was observed for ICH (p = 0.46). Similar results were found in the subgroup analysis by HAS-BLED score (p values [ 0.05 for subgroup differences; Table 3 ). Sensitivity analyses also yielded similar results to the main analyses (Table 3) .
Rivaroxaban versus dabigatran

Rivaroxaban versus apixaban
Compared with apixaban, no difference in risk of stroke or systemic embolism was found in rivaroxaban (HR = 1.09, 95% CI 0.96-1.24, p = 0.19; Fig. 1c and Table 2 ). However a significantly higher risk of major bleeding was observed in rivaroxaban (HR = 1.71, 95% CI 1.51-1.94, p \ 0.001; Fig. 1d and Table 2 ) with significant heterogeneity found (I 2 = 56%, p = 0.04). No analyses for effectiveness outcomes or subgroup analyses were conducted due to insufficient studies or data available. Similar results were found in sensitivity analyses (Table 3) .
Apixaban versus dabigatran
In comparison with dabigatran, apixaban was not significantly associated with decreased risk of stroke or systemic embolism (HR = 0.94, 95% CI 0.83-1.06, p = 0.32; Fig. 1e and Table 2 ), but significantly associated with decreased risk of major bleeding (HR = 0.80, 95% CI 0.68-0.95, p = 0.01; Fig. 1f and Table 2 ). There was significant heterogeneity found for risk of major bleeding: I 2 = 61%, p = 0Á03. No analyses for effectiveness outcomes or subgroup analyses were performed. Sensitivity analyses produced similar findings to the main analyses ( Table 3) .
Assessment of publication bias and quality of a body of evidence
There was no evidence of publication bias found in the comparison amongst NOACs, with all the p values of [ 0Á05 for Begg's and Egger's tests (Supplemental Figures 4-7) . The quality of a body of evidence across included studies was rated as low-quality for the effectiveness outcome of rivaroxaban versus dabigatran and for the safety outcomes of rivaroxaban versus apixaban or apixaban versus dabigatran, due to the non-randomized design and unexplained heterogeneity. The evidence for the safety outcome of rivaroxaban versus dabigatran was graded as moderate-quality because of the non-randomized design (Supplemental Table 2 ).
Discussion
In this systematic review and meta-analysis, we summarized the evidence from observational studies of direct comparative effectiveness and safety amongst NOACs in patients with AF. No significant differences in risk of stroke or systemic embolism were found between rivaroxaban versus dabigatran, rivaroxaban versus apixaban, or apixaban versus dabigatran. Apixaban was found to have the most favorable safety profile amongst the three NOACs.
Apixaban was associated with a lower risk of major bleeding when compared with dabigatran or rivaroxaban ( Table 2 ). This finding may provide some decision-making support for physicians regarding their choices amongst NOACs, especially when considering the equivalent effect of the NOACs on effectiveness outcomes. The evaluated risk of major bleeding and mortality in rivaroxaban compared with dabigatran or apixaban may reflect the true difference in safety outcomes between the three NOACs. The once-daily dosing of rivaroxaban and twice-daily administration of dabigatran might also explain the higher risk of major bleeding in rivaroxaban, given its higher peak in plasma concentrations than dabigatran [20] . However, the observed results (no difference in effectiveness, but better safety) between rivaroxaban and dabigatran or apixaban may also be partly due to selective prescribing. Patients in Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) were older and frailer, required more orthopedic procedures, and had more baseline comorbidities than in RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy) or Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE) [8] [9] [10] , therefore physicians may prefer prescribing rivaroxaban to patients at higher risk of adverse health outcomes [30, 32] . In addition, once-daily dosing may be preferred for patients on other multiple drugs or with memory problems, to decrease pill burden. Although all the included studies used multivariable or propensity score adjustment to estimate the relative effect, the non-randomized design could not fully adjust for the effect of selective prescribing or prevent the potential residual confounding.
The numbers of studies included for quantitative syntheses of the primary outcomes were relatively small ( Table 2 ). Three studies [27, 29, 36] investigating risk of major bleeding could not be used for meta-analyses, because two studies [27, 36] did not provide data on the relative effect and the other study [29] only reported adjusted ORs (rather than HRs). Nevertheless, they consistently reported higher incidence rates of major bleeding during follow-up in rivaroxaban compared with dabigatran or apixaban. Likewise, due to insufficient studies available and suboptimal reporting, no analyses of using standard NOAC doses or subgroup analyses could be conducted for rivaroxaban versus apixaban or apixaban versus dabigatran. Therefore the significant heterogeneity could not be further explored, leading to the quality of a body of evidence being low (Supplemental Table 2 ).
Three studies summarizing the observational evidence of direct comparisons amongst NOACs have been published [41] [42] [43] . Although our findings were in general agreement with their results, the other studies have limitations, either only exploring the comparison between rivaroxaban and dabigatran [42, 43] , or only assessing the safety profiles amongst NOACs [41, 43] . There are several studies using data from RCTs to indirectly compare efficacy and safety outcome between NOACs [12] [13] [14] [15] [16] [17] [18] . Our study found similar effectiveness but higher risk of major bleeding in rivaroxaban compared with dabigatran, which was not consistent with the indirect comparison studies that showed higher risk of stroke or systematic embolism in rivaroxaban but no difference in major bleeding [12, 13, 15, 18] . Indirect comparison should be interpreted with caution, given that such comparison is essentially observational design across trials and may suffer apparent and latent biases including confounding [21, 44] . Specifically, the difference in the three RCTs (ROCKET-AF, RE-LY, and ARISTOTLE) yielded the indirect comparison questionable and even misleading [19, 45] , because it remained unclear whether and to what extent the difference in risk of outcomes could be attributed to the drug alone. Indirect comparison studies can be used to generate hypotheses that are further corroborated ideally in direct comparative RCTs [18] . Given that no such RCT is available currently or in the near future, findings from realworld studies with direct comparative assessment amongst NOACs may assist in decision-making in clinical practice. The large-scale direct design with multivariable or b Fig. 1 Results of direct comparisons amongst NOACs: a results for risk of stroke or systemic embolism comparing rivaroxaban with dabigatran; b results for risk of major bleeding comparing rivaroxaban with dabigatran; c results for risk of stroke or systemic embolism comparing rivaroxaban with apixaban; d results for risk of major bleeding comparing rivaroxaban with apixaban; e results for risk of stroke or systemic embolism comparing apixaban with dabigatran; f results for risk of major bleeding comparing apixaban with dabigatran Fig. 1 continued propensity score adjustment in the relatively homogeneous patients for each individual study may provide more credible evidence than indirect comparison, although an observational study is prone to biases due to its non-randomization and should be interpreted with caution.
Moreover, four included studies evaluated the comparison between NOACs and warfarin and reported consistent findings with the respective trials [28, 30, 31, 37] . This would also support the validity of the included observational studies and our current review. However, further large-scale, well-designed and transparently-reported observational studies or eventually head-to-head clinical trials are needed to update the evidence and inform decision-making, because of insufficient studies or data available in our study including limited evidence for subgroup evaluations and for risks of MI and death.
Strengths and limitations
This study is the first systematic review to summarize evidence from observational studies for direct comparison amongst NOACs, to our knowledge. An exhaustive and comprehensive search was conducted to obtain all relevant and most-updated studies. Study processes including screening, data extraction and analyses were performed in duplicate with a good level of agreement. Results from sensitivity analyses supported the robustness of findings from the main analyses. Some limitations exist in our study. First, the non-randomized comparisons in observational studies may suffer from biases, which could impair the findings and thus weaken the strength of evidence. Secondly, due to limited studies or data, we could not further evaluate the comparative outcomes of interest amongst all NOACs, especially with no data on edoxaban available. Similarly, no analyses could be performed in subgroup populations including patients with or without renal dysfunction, with different sex, at low or high risk of stroke and/or major bleeding, with high or low drug adherence, with or without concomitant over-the-counter antiplatelets, and at different ages. Thirdly, the statistical methods used in the included studies including multivariable regression and propensity score methods were performed to estimate different relative treatment effects. For instance, the propensity score matching was used to estimate effects in the patients who received NOACs; the propensity score covariate adjustment was used for conditional effects within levels of the propensity scores; and the propensity score inverse probability of treatment weighting and the multivariable regression were used to estimate effects in all the patients with AF who were eligible for a NOAC [46] . However no analyses could be conducted to compare the different targeted effects due to the small number of included studies. Furthermore, all the included studies used ICD-9-CM or ICD-10-CM (International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification) codes to identify outcomes and no chart reviews were performed to validate outcome measures, which was a common limitation of observational analyses based on electronic health databases. For example, it was reported that the outcome data (incidences of cardiovascular and bleeding events) identified from medical claims after MI were generally lower than from physician adjudication [47] . Therefore caution is needed when interpreting such observational studies that depend on the data from electronic health databases alone. Additionally, because the follow-up periods were relatively short ranging from 110 to 400 days (Table 1) , little was known about the long-term comparative effectiveness and safety between NOACs in patients with AF in the current study.
Conclusion
This systematic review and meta-analysis based on observational studies of direct comparative effectiveness and safety amongst NOACs in patients with AF found increased risk of major bleeding with rivaroxaban compared to dabigatran and apixaban. Apixaban was associated with lower risk of major bleeding than dabigatran. No significant difference was observed in risk of stroke or systemic embolism amongst the three NOACs. Such findings may provide some decision-making support for physicians regarding their choices amongst NOACs in patients with AF.
